Portolan Capital Management LLC Decreases Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Portolan Capital Management LLC lowered its stake in OrthoPediatrics Corp. (NASDAQ:KIDSFree Report) by 33.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 205,365 shares of the company’s stock after selling 102,734 shares during the quarter. Portolan Capital Management LLC owned about 0.85% of OrthoPediatrics worth $4,760,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. R Squared Ltd acquired a new stake in OrthoPediatrics in the fourth quarter valued at approximately $48,000. KLP Kapitalforvaltning AS acquired a new stake in OrthoPediatrics during the 4th quarter valued at $79,000. BNP Paribas Financial Markets grew its holdings in OrthoPediatrics by 125.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after purchasing an additional 1,929 shares in the last quarter. AlphaCentric Advisors LLC acquired a new position in OrthoPediatrics in the 4th quarter worth $171,000. Finally, Wells Fargo & Company MN boosted its position in OrthoPediatrics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company’s stock valued at $228,000 after buying an additional 2,338 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KIDS. Stifel Nicolaus dropped their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Lake Street Capital began coverage on OrthoPediatrics in a report on Monday, April 7th. They set a “buy” rating and a $37.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a research note on Wednesday, April 9th. Finally, Truist Financial dropped their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a research note on Friday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

Get Our Latest Analysis on OrthoPediatrics

OrthoPediatrics Trading Down 1.1 %

NASDAQ:KIDS opened at $21.16 on Monday. The company has a market cap of $513.91 million, a PE ratio of -17.20 and a beta of 1.17. The business’s 50 day moving average is $24.14 and its two-hundred day moving average is $24.72. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 52 week low of $20.78 and a 52 week high of $35.99.

OrthoPediatrics (NASDAQ:KIDSGet Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. During the same period last year, the business posted ($0.23) earnings per share. On average, analysts predict that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Insider Activity at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. The trade was a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now owns 110,767 shares in the company, valued at approximately $2,753,667.62. This represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock valued at $589,978 in the last quarter. Insiders own 31.80% of the company’s stock.

OrthoPediatrics Company Profile

(Free Report)

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

See Also

Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDSFree Report).

Institutional Ownership by Quarter for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.